Tegafur
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Tegafur: Cecum villous adenoma
One-Sentence Summary
Tegafur is an oral fluoropyrimidine prodrug that the body converts to the antimetabolite 5-fluorouracil (5-FU), and it is used in cancer treatment. The TxGNN model predicts it may be effective for cecum villous adenoma, but no clinical trials and no publications currently support this prediction. The prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Cecum villous adenoma |
| TxGNN Prediction Score | 0.9986 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (3 of 3) – CDSCO approval status is not included in this data |
| Number of Listed Products | 3 (valid: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for tegafur is not available in the data compiled for this report. Based on its known drug class, tegafur is a prodrug of 5-FU. Once converted, 5-FU interferes with DNA synthesis in rapidly dividing cells, which is the basis of its use against malignant tumours.
The predicted condition is a villous adenoma of the cecum, a benign precursor lesion of the large bowel. A model may score it highly because it sits close to other bowel diseases that are treated with fluoropyrimidines. That is a statistical association, not evidence that the drug works here.
Mechanistically, the rationale is weak. Villous adenomas are normally managed by endoscopic or surgical removal, not by chemotherapy. An antimetabolite given to treat a benign lesion would expose patients to toxicity with no established benefit. The high score (0.9986) should therefore be read as a hypothesis for further review, not as a treatment recommendation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 217926 | Tegafi 100mg/224mg Capsule (Intas Pharmaceuticals Ltd) | Strip of 14 capsules | Not stated in the data compiled for this report |
| 122146 | Luporal Capsule (Lupin Ltd) | Strip of 10 capsules | Not stated in the data compiled for this report |
| 232025 | Uratuf 100mg/224mg Capsule (Dr Reddy’s Laboratories Ltd) | Strip of 14 capsules | Not stated in the data compiled for this report |
All three licences are currently valid, and all are for oral capsule products.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (fluoropyrimidine class) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Complete blood count, liver and renal function (standard monitoring for fluoropyrimidines; confirm against the package insert) |
| Handling Protection | Follow cytotoxic drug handling regulations |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a very high model score (0.9986) but no supporting clinical trials or publications, so the evidence level is L5. The target condition is a benign lesion normally treated by removal, which makes the case for systemic chemotherapy weak.
To proceed, the following is needed:
- Any clinical or observational study that directly examines tegafur in cecum villous adenoma
- A clear clinical justification for using chemotherapy rather than endoscopic or surgical management in a benign lesion
- Detailed mechanism-of-action data
- Package insert safety information (warnings and contraindications) for the marketed products
- A benefit-risk assessment of cytotoxic exposure in a non-malignant population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.